Skip to main content
. 2023 Jun 30;12(7):1436–1444. doi: 10.21037/tlcr-23-10

Table 2. Best response to crizotinib therapy.

Efficacy ROS1, n=26 ALK, n=42 P value
Response
   CR 2 (8%) 5 (12%)
   PR 16 (62%) 24 (57%)
   SD 4 (15%) 5 (12%)
   PD 2 (8%) 3 (7%)
   NE 2 (8%) 5 (12%)
Clinical benefit
   ORR 69% 69% 0.987
   DCR 85% 81% 0.484

ALK, anaplastic lymphoma kinase; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not estimable; ORR, objective response rate; DCR, disease control rate.